Please login to the form below

Not currently logged in
Email:
Password:

BMS melanoma drug meets goal

Bristol-Myers Squibb has announced that its investigational melanoma drug ipilimumab has performed well in a phase III study

Bristol-Myers Squibb (BMS) has announced that its investigational melanoma drug ipilimumab has performed well in a phase III study.

The trial, known as study 024, showed that ipilimumab improved overall survival in previously untreated patients with unresectable stage III or stage IV melanoma. The trial compared the BMS drug in combination with dacarbazine chemotherapy to the chemotherapy regimen alone.

BMS said it plans to submit an abstract of the data to the American Society of Clinical Oncology for presentation at the society's Annual Meeting this summer.

BMS has already filed the drug with the US Food and Drug Administration (FDA), as well as regulatory authorities in a number of other countries, as a therapy for previously treated unresectable stage III or stage IV melanoma patients. In the US, a decision regarding the drug for that indication is due within days.

22nd March 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....